Literature DB >> 2322109

Source of plasma chromogranin A elevation in gastrinoma patients.

B E Stabile1, T J Howard, E Passaro, D T O'Connor.   

Abstract

Chromogranin A (Cg A) is a protein that is coreleased with peptide hormones from gut endocrine cells and tumors. Plasma levels of Cg A, pepsinogen group I, and gastrin were measured in 31 patients with gastrinoma. Mean Cg A level in 10 patients with gastrinoma who were not operated on was 169 +/- 32 ng/mL, while in 9 control patients it was 28 +/- 5 ng/mL. In 18 patients with gastrinoma with residual tumor after total gastrectomy, the mean Cg A level was 45 +/- 6 ng/mL, and in 10 patients with normal gastrin levels after total gastrectomy and tumor excision, the mean Cg A level was 40 +/- 4 ng/mL. In 7 patients in whom pregastrectomy and postgastrectomy Cg A levels were measured, the mean reduction was 94 +/- 27 ng/mL, or 66%. There was no correlation between Cg A levels and amount of tumor, presence of metastases, or multiple endocrine neoplasia type I syndrome. There was a significant correlation between Cg A and pepsinogen I levels but no correlation between Cg A and gastrin levels. The results suggest that the elevated plasma Cg A levels in patients with gastrinoma are determined primarily by the trophic effects of gastrin on gastric enterochromaffinlike cells rather than by corelease from the gastrin-producing tumor itself.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322109     DOI: 10.1001/archsurg.1990.01410160037007

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  6 in total

1.  Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumors.

Authors:  Christine S Landry; Keith Cavaness; Scott Celinski; John Preskitt
Journal:  Gland Surg       Date:  2014-11

Review 2.  Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I.

Authors:  M Pipeleers-Marichal; C Donow; P U Heitz; G Klöppel
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

3.  Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.

Authors:  F Panzuto; C Severi; R Cannizzaro; M Falconi; S Angeletti; A Pasquali; V D Corleto; B Annibale; A Buonadonna; P Pederzoli; G Delle Fave
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

4.  Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract.

Authors:  G Schürmann; U Raeth; B Wiedenmann; H Buhr; C Herfarth
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

5.  Effects of Helicobacter pylori infection and long-term proton pump inhibitor use on enterochromaffin-like cells.

Authors:  Mehmet Bektaş; Nurşen Saraç; Hülya Cetinkaya; Murat Törüner; Esra Erdemli; Onur Keskin; Irfan Soykan; Esen Ismet Oktay; Esin Korkut; Yusuf Ustün; Kadir Bahar
Journal:  Ann Gastroenterol       Date:  2012

Review 6.  Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.

Authors:  Johannes Hofland; Gregory Kaltsas; Wouter W de Herder
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.